There are currently 104 active clinical trials seeking participants for Asthma research studies. The states with the highest number of trials for Asthma participants are California, Texas, Florida and Ontario.
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
NCT00595491
Recruiting
Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation. This work is designed to identify airway factors that are responsible for recruiting cells and associate their airway presence with atopy and asthma.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
11/03/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Asthma
Register for Updates
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
NCT01225913
Recruiting
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists. The investigators are interested in determining whether the large and/or small airways are the predominant site of airflow limitation. The investigators are also interested in determining whet... Read More
Gender:
All
Ages:
Between 10 years and 80 years
Trial Updated:
10/25/2023
Locations: Arthur F Gelb Medical Corporation, Lakewood, California
Conditions: Asthma
Register for Updates
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
NCT00576069
Recruiting
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists and long acting muscarinic antagonists. We are interested in determining whether the large and/or small airways are the predominant site of airflow limitation. We are also interested in determi... Read More
Gender:
All
Ages:
Between 10 years and 95 years
Trial Updated:
10/25/2023
Locations: Arthur F Gelb Medical Corporation, Lakewood, California
Conditions: Asthma
Register for Updates
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
NCT05243680
Recruiting
The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744.
Gender:
All
Ages:
12 years and above
Trial Updated:
10/13/2023
Locations: GSK Investigational Site, Lancaster, California +131 locations
Conditions: Asthma
Register for Updates
Simultaneously Implementing Pathways for Improving Asthma, Pneumonia, and Bronchiolitis Care for Hospitalized Children
NCT05206695
Recruiting
This study's objective is to identify and test pragmatic and sustainable strategies for implementing a multi-condition clinical pathway intervention for children hospitalized with asthma, pneumonia, or bronchiolitis in community hospitals. The hypothesis is that the multi-condition pathway intervention will be associated with significantly greater increases in clinicians' adoption of evidence-based practices compared to control. The study is a pragmatic, cluster-randomized trial in US community... Read More
Gender:
All
Ages:
17 years and below
Trial Updated:
10/12/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: Asthma, Pneumonia, Bronchiolitis
Register for Updates
Vaginal Microbiome Exposure and Immune Responses in C-section Infants
NCT03567707
Recruiting
The purpose of this research study is to assess at how differences in the microbiome (naturally occurring bacteria) of a baby may protect, or put a baby at risk, for allergic problems. The microbiome refers to the thousands of bacteria and molds that live in and on our bodies. The microbiome plays an important role in our health. Differences in the microbiome can affect our immune system in ways that might make some people more likely to get allergies and asthma. Early life events and exposures... Read More
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
10/10/2023
Locations: Mount Sinai West, New York, New York +1 locations
Conditions: Allergic Diseases, Asthma
Register for Updates
Innate Immunity in Allergic Asthma
NCT06068335
Recruiting
The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/09/2023
Locations: University of Central Florida, Orlando, Florida
Conditions: Asthma
Register for Updates
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
NCT04743791
Recruiting
Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, Pennsylvania
Conditions: Asthma
Register for Updates
AIM2ACT: A Mobile Health Tool to Help Adolescents Self-Manage Asthma
NCT04448002
Recruiting
The aim is to test the efficacy of AIM2ACT and long-term maintenance of treatment effects in a fully-powered randomized controlled trial with 160 early adolescents with poorly controlled persistent asthma, ages 12-15 years, and a caregiver
Gender:
All
Ages:
Between 12 years and 70 years
Trial Updated:
09/15/2023
Locations: UF Health Pediatrics, Gainesville, Florida
Conditions: Asthma
Register for Updates
A Study of Patients With Chronic Disease
NCT04263727
Recruiting
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared study infrastructure supports progressive development of the registry across the spectrum of chronic diseases.
Gender:
All
Ages:
All
Trial Updated:
08/24/2023
Locations: Asthma and Allergy Associates, PC, Colorado Springs, Colorado +4 locations
Conditions: Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF, COPD, Respiratory Disease
Register for Updates
Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma
NCT05035862
Recruiting
This study is a two strata, dose escalation Phase I clinical trial designed to assess the safety and determine the maximal tolerated dose (MTD) of allogenic cord tissue derived MSCs (cMSCs, stratum 1) and allogeneic, interferon-γ primed bone marrow MSCs (γMSCs, stratum 2). Each stratum is designed to independently accrue 3 children at a dose level 1 of 2x106 cells/kg and 6 children at dose level 2 of 10x106 cells/kg, resulting in 9 children in each stratum. The primary objectives are to determin... Read More
Gender:
All
Ages:
Between 18 years and 30 years
Trial Updated:
08/23/2023
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Asthma
Register for Updates
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
NCT05254314
Recruiting
This is a randomized placebo-controlled trial of semaglutide, an FDA-approved therapy for the treatment of type 2 diabetes mellitus and obesity, in adults with symptomatic asthma despite the use of inhaled steroids and with excess body weight. This study will test the central hypothesis that semaglutide will improve asthma control and reduce airway inflammation due to direct effects on the respiratory tract in adult asthma associated with obesity.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/14/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Asthma
Register for Updates